Disposition of 3200 shares by Pamela Cramer of Rhythm Pharmaceuticals at 50.0056 subject to Rule 16b-3
RYTM Stock | USD 62.04 0.21 0.34% |
About 57% of Rhythm Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Rhythm Pharmaceuticals suggests that many traders are alarmed. Rhythm Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Rhythm Pharmaceuticals. Many technical investors use Rhythm Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Rhythm |
Filed transaction by Rhythm Pharmaceuticals Officer Chief Human Resources Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3
Read at macroaxis.com
Cash Flow Correlation
Rhythm Pharmaceuticals' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Rhythm Pharmaceuticals' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Rhythm Pharmaceuticals Fundamental Analysis
We analyze Rhythm Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rhythm Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rhythm Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Flow From Operations
Cash Flow From Operations Comparative Analysis
Rhythm Pharmaceuticals is currently under evaluation in cash flow from operations category among its peers. Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Rhythm Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Rhythm Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Rhythm Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Rhythm Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Rhythm Pharmaceuticals Related Equities
MGTX | MeiraGTx Holdings | 3.36 | ||||
BDTX | Black Diamond | 3.11 | ||||
ARVN | Arvinas | 2.85 | ||||
CGEM | Cullinan Oncology | 2.75 | ||||
PLRX | Pliant Therapeutics | 2.00 | ||||
STOK | Stoke Therapeutics | 1.68 | ||||
RCKT | Rocket Pharmaceuticals | 1.34 | ||||
SNDX | Syndax Pharmaceuticals | 1.27 | ||||
VTYX | Ventyx Biosciences | 1.13 | ||||
SLDB | Solid Biosciences | 0.18 | ||||
NUVL | Nuvalent | 0.08 | ||||
AKRO | Akero Therapeutics | 0.22 | ||||
INZY | Inozyme Pharma | 0.37 | ||||
RNA | Avidity Biosciences | 0.69 | ||||
QURE | Uniqure NV | 0.83 | ||||
KNSA | Kiniksa Pharmaceuticals | 1.08 | ||||
ACLX | Arcellx | 1.12 | ||||
RVMD | Revolution Medicines | 1.25 | ||||
VRDN | Viridian Therapeutics | 1.46 | ||||
RLAY | Relay Therapeutics | 2.08 | ||||
PTGX | Protagonist Therapeutics | 2.56 |
Check out Rhythm Pharmaceuticals Hype Analysis, Rhythm Pharmaceuticals Correlation and Rhythm Pharmaceuticals Performance. To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rhythm Pharmaceuticals. If investors know Rhythm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rhythm Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.32) | Revenue Per Share 1.863 | Quarterly Revenue Growth 0.478 | Return On Assets (0.46) | Return On Equity (1.48) |
The market value of Rhythm Pharmaceuticals is measured differently than its book value, which is the value of Rhythm that is recorded on the company's balance sheet. Investors also form their own opinion of Rhythm Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rhythm Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rhythm Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rhythm Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rhythm Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rhythm Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rhythm Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.